Oligonucleotide End Caps for Nuclease Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oligonucleotides face challenges in maintaining stability and effectiveness due to chemical and nuclease digestion, leading to short half-life and increased off-target effects, which limits their ability to inhibit gene expression effectively.
Innovation Solution
The use of non-nucleosidic end caps, such as those based on a pyrrolidine ring, attached to the 3′ or 2′ end of oligonucleotides via linkages like phosphodiester, sulfur, amino, or ether linkages, enhances resistance to nuclease digestion and increases the half-life of oligonucleotides in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If oligonucleotides are used without end cap modifications, then they can be synthesized and applied for gene inhibition, but they suffer from short half-life due to chemical and nuclease digestion
Solution Approach 1:
An end cap group is introduced as an intermediary protective element at the terminus of the oligonucleotide. This end cap acts as a mediator that shields the vulnerable 3′ or 2′ end from nuclease attack and chemical degradation, thereby extending the half-life and improving stability without interfering with the oligonucleotide's primary function of gene inhibition
Solution Approach 2:
The chemical structure at the terminus of the oligonucleotide is modified by attaching various end cap groups (such as pyrrolidine rings, phosphodiester linkages, sulfur linkages, amino linkages, or ether linkages). This parameter change in the molecular structure fundamentally alters the degradation kinetics, transforming the oligonucleotide from a labile molecule with short half-life to a stable molecule with extended in vivo persistence
2Reliability
If oligonucleotides are modified to increase stability and half-life, then their bioavailability and effectiveness improve, but the complexity of synthesis and structure increases
Solution Approach 1:
Rather than modifying the entire oligonucleotide structure, the end cap modification is applied locally at only the terminus (3′ or 2′ end). This localized modification approach confers enhanced stability and bioavailability to the critical region that requires protection, while leaving the rest of the oligonucleotide structure relatively simple and synthesizable using standard protocols
Solution Approach 2:
The oligonucleotide is transformed into a composite structure by combining the nucleic acid sequence with a chemically distinct end cap group. This composite architecture integrates the functional oligonucleotide portion with the protective end cap portion, achieving enhanced stability and bioavailability through the synergistic combination of different chemical components
Data Source
AI summary
Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.